Report cover image

Exocrine Pancreatic Insufficiency Treatment Market

Publisher Global Market Insights
Published Nov 05, 2024
Length 101 Pages
SKU # GMI19407247

Description

Exocrine Pancreatic Insufficiency Treatment Market


The Global Exocrine Pancreatic Insufficiency Treatment Market reached approximately USD 2.7 billion in 2023, with a projected growth rate of 5.6% CAGR from 2024 to 2032. Exocrine pancreatic insufficiency, characterized by a lack of pancreatic enzymes critical for nutrient digestion and absorption, is managed through a combination of medical and dietary approaches. Treatment strategies for EPI aim to reduce symptoms, boost nutrient absorption, and improve the quality of life for those affected by the condition.Significant advancements in diagnostic techniques for EPI are improving detection and supporting more timely, effective treatments. Latest research has aimed at detecting definite biomarkers, which are transforming pancreatic function assessments and facilitating earlier diagnosis. Fecal elastase-1 has emerged as an essential biomarker, with low levels indicating pancreatic insufficiency, enhancing diagnostic precision and contributing to market expansion.The market is segmented by treatment type into nutritional management and pancreatic enzyme replacement therapy (PERT), with the PERT segment leading in market revenue, reaching USD 2.3 billion in 2023. PERT aids in restoring the body’s ability to digest essential nutrients, alleviating common symptoms such as bloating and steatorrhea. By enabling proper absorption of fats, proteins, and carbohydrates, PERT prevents complications associated with EPI, including malnutrition, vitamin deficiencies, and unintended weight loss, significantly improving patients' quality of life.In terms of drug types, the market includes key medications designed for PERT, each offering unique formulations to enhance nutrient absorption and relieve symptoms associated with EPI. With enzymes like lipase, protease, and amylase, these therapies are optimized for efficiency, utilizing enteric-coated capsules to ensure enzymes are effectively released in the small intestine where digestion occurs. These formulations are available in various dosages, allowing for treatment customization based on individual patient requirements.North America accounted for a major share of the EPI treatment market in 2023, with an anticipated growth reaching USD 2.4 billion by 2032. The region benefits from advanced healthcare infrastructure, extensive research initiatives, and broad access to PERT, driving growth in EPI treatment availability. Additionally, comprehensive insurance coverage and well-established healthcare systems in North America enhance patient access to specialized medications and care, further supporting market expansion and improved patient outcomes. As advancements in diagnostic methods and therapeutic options continue to evolve, the global EPI treatment market is expected to see steady growth.

Table of Contents

101 Pages
Chapter 1 Methodology
1.1 Market segmentation
1.2 Market definitions
1.3 Research design
1.4 Market size estimates and calculations
1.4.1 Company share analysis
1.4.2 Prevalence based approach
1.5 Key trends for market estimates
1.6 Forecast model
1.7 Primary research & validation
1.7.1 Primary sources
1.7.2 Data mining sources
1.7.2.1 Paid sources
1.7.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis, 2021 - 2032
2.2 Treatment trends
2.3 Drug type
2.4 Symptom trends
2.5 Distribution channel trends
2.6 Regional trends
Chapter 3 Exocrine Pancreatic Insufficiency Treatment Market Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of chronic pancreatitis (CP) and cystic fibrosis
3.2.1.2 Growing aging population
3.2.1.3 Advancements in diagnosis
3.2.1.4 Technological advancements in pharmaceutical industry
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Limited awareness and education
3.3.1 By treatment
3.3.2 By drug type
3.3.3 By symptom
3.3.4 By distribution channel
3.4 Regulatory landscape
3.4.1 U.S.
3.4.2 Europe
3.5 Technology landscape
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.1.1 AbbVie Inc.
4.1.2 Abbott Laboratories
4.1.3 Nestlé S.A.
4.1.4 Viatris Inc.
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Exocrine Pancreatic Insufficiency Treatment Market, By Treatment
5.1 Nutritional management
5.2 Pancreatic enzyme replacement therapy (PERT)
Chapter 6 Exocrine Pancreatic Insufficiency Treatment Market, By Drug Type
6.1 Creon
6.2 Zenpep
6.3 Pancreaze
6.4 Viokace
6.5 Other drug types
Chapter 7 Exocrine Pancreatic Insufficiency Treatment Market, By Symptom
7.1 Abdominal pain
7.2 Constipation
7.3 Diarrhea
7.4 Fatty stools
7.5 Weight loss
7.6 Other symptoms
Chapter 8 Exocrine Pancreatic Insufficiency Treatment Market, By Distribution Channel
8.1 Hospital pharmacies
8.2 Retail pharmacies
8.3 Online pharmacies
Chapter 9 Exocrine Pancreatic Insufficiency Treatment Market, By Region
9.1 North America
9.2 Europe
9.3 Asia Pacific
9.4 Latin America
9.5 Middle East and Africa
Chapter 10 Company Profile
10.1 Abbott Laboratories
10.1.1 Global overview
10.1.2 Business overview
10.1.3 Financial data
10.1.3.1 Annual sales revenue, 2023-2020 (USD Million)
10.1.4 Product landscape
10.1.5 SWOT analysis
10.2 AbbVie Inc.
10.2.1 Global overview
10.2.2 Business overview
10.2.3 Financial data
10.2.3.1 Annual sales revenue, 2023-2020 (USD Million)
10.2.4 Product landscape
10.2.5 SWOT analysis
10.3 Digestive Care, Inc.
10.3.1 Global overview
10.3.2 Business overview
10.3.3 Financial data
10.3.4 Product landscape
10.3.5 SWOT analysis
10.4 Essential Pharma
10.4.1 Global overview
10.4.2 Business overview
10.4.3 Financial data
10.4.4 Product landscape
10.4.5 SWOT analysis
10.5 Nestlé S.A.
10.5.1 Global overview
10.5.2 Business overview
10.5.3 Financial data
10.5.3.1 Annual sales revenue, 2023-2020 (USD Million)
10.5.4 Product landscape
10.5.5 Strategic outlook
10.5.6 SWOT analysis
10.6 Nordmark Pharma GmbH
10.6.1 Global overview
10.6.2 Business overview
10.6.3 Financial data
10.6.4 Product landscape
10.6.5 SWOT analysis
10.7 Sun Pharmaceutical Industries Ltd
10.7.1 Global overview
10.7.2 Business overview
10.7.3 Financial data
10.7.3.1 Annual sales revenue, 2023-2020 (USD Million)
10.7.4 Product landscape
10.7.5 SWOT analysis
10.8 Viatris Inc.
10.8.1 Global overview
10.8.2 Business overview
10.8.3 Financial data
10.8.3.1 Annual sales revenue, 2023-2020 (USD Million)
10.8.4 Product landscape
10.8.5 SWOT analysis
10.9 VIVUS LLC
10.9.1 Global overview
10.9.2 Business overview
10.9.3 Financial data
10.9.4 Product landscape
10.9.5 SWOT analysis
10.10 Zentiva Pharma UK Ltd
10.10.1 Global overview
10.10.2 Business overview
10.10.3 Financial data
10.10.4 Product landscape
10.10.5 SWOT analysis

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us